ERBB2 and gastric cancer: HER2 positivity (immunohistochemistry score 3+ and/or DNA amplification) was 18%, which was identical to previous studies that reported that HER2 positivity (immunohistochemistry score 3+ and/or FISH-positive) in Japanese patients with GC was 10–20%.